{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:48:04Z","timestamp":1789753684885,"version":"4.0.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"DOI":"10.1007\/s00702-025-02983-3","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T13:22:49Z","timestamp":1752844969000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cognitive disorders and parkinson\u2019s disease: a literature review"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5317-7369","authenticated-orcid":false,"given":"Roland Dominic G.","family":"Jamora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9040-0871","authenticated-orcid":false,"given":"Liamuel Giancarlo V.","family":"Untalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna Mae Lyn B.","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis C. S.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"2983_CR1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1001\/archneur.60.3.387","volume":"60","author":"D Aarsland","year":"2003","unstructured":"Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-S\u00f8rensen P (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60:387\u2013392. https:\/\/doi.org\/10.1001\/archneur.60.3.387","journal-title":"Arch Neurol"},{"key":"2983_CR2","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1002\/mds.20527","volume":"20","author":"D Aarsland","year":"2005","unstructured":"Aarsland D, Zaccai J, Brayne C (2005) A systematic review of prevalence studies of dementia in parkinson\u2019s disease. Mov Disord 20:1255\u20131263. https:\/\/doi.org\/10.1002\/mds.20527","journal-title":"Mov Disord"},{"key":"2983_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3233\/JPD-171250","volume":"8","author":"H Alzahrani","year":"2018","unstructured":"Alzahrani H, Venneri A (2018) A cognitive rehabilitation in parkinson\u2019s disease: a systematic review. J Park Dis 8:233\u2013245. https:\/\/doi.org\/10.3233\/JPD-171250","journal-title":"J Park Dis"},{"key":"2983_CR4","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1212\/WNL.0000000000000842","volume":"83","author":"JB Anang","year":"2014","unstructured":"Anang JB, Gagnon JF, Bertrand JA et al (2014) Predictors of dementia in Parkinson disease: a prospective cohort study. Neurology 83:1253\u20131260. https:\/\/doi.org\/10.1212\/WNL.0000000000000842","journal-title":"Neurology"},{"key":"2983_CR5","unstructured":"Anand S, Schoo C (2024) Mild cognitive impairment. StatPearls Publishing. Retrieved April 4, 2025, from http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK599514"},{"key":"2983_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/ane.12590","volume":"135","author":"AD Andersen","year":"2017","unstructured":"Andersen AD, Binzer M, Stenager E, Gramsbergen JB (2017) Cerebrospinal fluid biomarkers for parkinson\u2019s disease - a systematic review. Acta Neurol Scand 135:34\u201356. https:\/\/doi.org\/10.1111\/ane.12590","journal-title":"Acta Neurol Scand"},{"key":"2983_CR7","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jns.2016.11.068","volume":"372","author":"T Baba","year":"2017","unstructured":"Baba T, Hosokai Y, Nishio Y et al (2017) Longitudinal study of cognitive and cerebral metabolic changes in parkinson\u2019s disease. J Neurol Sci 372:288\u2013293. https:\/\/doi.org\/10.1016\/j.jns.2016.11.068","journal-title":"J Neurol Sci"},{"key":"2983_CR8","doi-asserted-by":"publisher","first-page":"769","DOI":"10.2165\/11594110-000000000-00000","volume":"28","author":"C Ballard","year":"2011","unstructured":"Ballard C, Zahn Z, Corbett A (2011) Treatment of dementia with lewy bodies and parkinson\u2019s disease dementia. Drugs Aging 28:769\u2013777. https:\/\/doi.org\/10.2165\/11594110-000000000-00000","journal-title":"Drugs Aging"},{"key":"2983_CR9","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1002\/mds.23919","volume":"26","author":"P Barone","year":"2011","unstructured":"Barone P, Aarsland D, Burn D, Emre M, Kulisevsky J, Weintraub D (2011) Cognitive impairment in nondemented parkinson\u2019s disease. Mov Disord 26:2483\u20132495. https:\/\/doi.org\/10.1002\/mds.23919","journal-title":"Mov Disord"},{"key":"2983_CR10","doi-asserted-by":"publisher","first-page":"105385","DOI":"10.1016\/j.parkreldis.2023.105385","volume":"112","author":"E Bayram","year":"2023","unstructured":"Bayram E, Batzu L, Tilley B et al (2023) Clinical trials for cognition in parkinson\u2019s disease: where are we and how can we do better? Parkinsonism Relat Disoder 112:105385. https:\/\/doi.org\/10.1016\/j.parkreldis.2023.105385","journal-title":"Parkinsonism Relat Disoder"},{"key":"2983_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s10072-018-3628-3","volume":"40","author":"ML Bianchi","year":"2019","unstructured":"Bianchi ML, Riboldazzi G, Mauri M, Versino M (2019) Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic parkinson\u2019s disease. Neurol Sci 40:275\u2013279. https:\/\/doi.org\/10.1007\/s10072-018-3628-3","journal-title":"Neurol Sci"},{"key":"2983_CR12","doi-asserted-by":"publisher","first-page":"e157074","DOI":"10.1172\/JCI157074","volume":"132","author":"S Booth","year":"2022","unstructured":"Booth S, Park KW, Lee CS, Ko JH (2022) Predicting cognitive decline in parkinson\u2019s disease using FDG-PET-based supervised learning. J Clin Invest 132:e157074. https:\/\/doi.org\/10.1172\/JCI157074","journal-title":"J Clin Invest"},{"key":"2983_CR13","doi-asserted-by":"publisher","first-page":"117177","DOI":"10.1016\/j.jns.2020.117177","volume":"419","author":"PR Brand\u00e3o","year":"2020","unstructured":"Brand\u00e3o PR, Munhoz RP, Grippe TC et al (2020) Cognitive impairment in parkinson\u2019s disease: a clinical and pathyphysiological overview. J Neurol Sci 419:117177. https:\/\/doi.org\/10.1016\/j.jns.2020.117177","journal-title":"J Neurol Sci"},{"key":"2983_CR14","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1212\/01.wnl.0000306632.43729.24","volume":"70","author":"TC Buter","year":"2008","unstructured":"Buter TC, van den Hout A, Matthews FE, Larsen JP, Brayne C, Aarsland D (2008) Dementia and survival in Parkinson disease: a 12-year population study. Neurology 70:1017\u20131022. https:\/\/doi.org\/10.1212\/01.wnl.0000306632.43729.24","journal-title":"Neurology"},{"key":"2983_CR15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","volume":"14","author":"P Calabresi","year":"2023","unstructured":"Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V (2023) Alpha-synuclein in Parkinson disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis 14:176. https:\/\/doi.org\/10.1038\/s41419-023-05672-9","journal-title":"Cell Death Dis"},{"key":"2983_CR16","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1093\/brain\/awr031","volume":"134","author":"Y Compta","year":"2011","unstructured":"Compta Y, Parkkinen L, O\u2019Sullivan SS et al (2011) Lewy- and Alzheimer-type pathologies in parkinson\u2019s disease dementia: which is more important? Brain J Neurol 134:1493\u20131505. https:\/\/doi.org\/10.1093\/brain\/awr031","journal-title":"Brain J Neurol"},{"key":"2983_CR17","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1016\/j.biopsych.2011.03.028","volume":"69","author":"R Cools","year":"2011","unstructured":"Cools R, D\u2019Esposito M (2011) Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biol Psychiatr 69:e113\u2013e125. https:\/\/doi.org\/10.1016\/j.biopsych.2011.03.028","journal-title":"Biol Psychiatr"},{"key":"2983_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/ane.12375","volume":"132","author":"ME Domell\u00f6f","year":"2015","unstructured":"Domell\u00f6f ME, Ekman U, Forsgren L, Elgh E (2015) Cognitive function in the early phase of parkinson\u2019s disease: a five-year follow up. Acta Neurol Scand 132:79\u201388. https:\/\/doi.org\/10.1111\/ane.12375","journal-title":"Acta Neurol Scand"},{"key":"2983_CR19","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/mds.21507","volume":"22","author":"M Emre","year":"2007","unstructured":"Emre M, Aarsland D, Brown R et al (2007) Clinical diagnostic criteria for dementia associated with parkinson\u2019s disease. Mov Disord 22:1689\u20131707. https:\/\/doi.org\/10.1002\/mds.21507","journal-title":"Mov Disord"},{"key":"2983_CR20","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.3390\/brainsci14121163","volume":"14","author":"ED Frost","year":"2024","unstructured":"Frost ED, Shi SX, Byroju VV et al (2024) Galanatamine-memantine combination in the treatment of parkinson\u2019s disease dementia: a systematic review and meta-analysis. Brain Sci 14:1163. https:\/\/doi.org\/10.3390\/brainsci14121163","journal-title":"Brain Sci"},{"key":"2983_CR21","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1007\/s00259-012-2198-5","volume":"39","author":"D Garcia-Garcia","year":"2012","unstructured":"Garcia-Garcia D, Clavero P, Gasca Salas S et al (2012) Posterior parietooccipital hypometabolism May differentiate mild cognitive impairment from dementia in parkinson\u2019s diseae. Eur J Nucl Med Mol Imaging 39:1767\u20131777. https:\/\/doi.org\/10.1007\/s00259-012-2198-5","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2983_CR22","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1002\/mds.29918","volume":"39","author":"LL Gibson","year":"2024","unstructured":"Gibson LL, Weintraub D, Lemmen R et al (2024) Risk of dementia in parkinson\u2019s disease: a systematic review and meta-analysis. Mov Disord 39:1697\u20131709. https:\/\/doi.org\/10.1002\/mds.29918","journal-title":"Mov Disord"},{"key":"2983_CR23","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1093\/brain\/awv104","volume":"138","author":"J Gratwicke","year":"2015","unstructured":"Gratwicke J, Jahanshahi M, Foltynie T (2015) Parkinson\u2019s disease dementia: a neural networks perspective. Brain J Neurol 138:1454\u20131476. https:\/\/doi.org\/10.1093\/brain\/awv104","journal-title":"Brain J Neurol"},{"key":"2983_CR24","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/mds.21956","volume":"23","author":"MA Hely","year":"2008","unstructured":"Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of parkinson\u2019s disease: the inevitability of dementia at 20 years. Mov Disord 23:837\u2013844. https:\/\/doi.org\/10.1002\/mds.21956","journal-title":"Mov Disord"},{"key":"2983_CR25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/j.1600-0404-1986.tb03257.x","volume":"73","author":"M Hietanen","year":"1986","unstructured":"Hietanen M, Ter\u00e4v\u00e4inen H (1986) Cognitive performance in early parkinson\u2019s disease. Acta Neurol Scand 73:151\u2013159. https:\/\/doi.org\/10.1111\/j.1600-0404-1986.tb03257.x","journal-title":"Acta Neurol Scand"},{"key":"2983_CR26","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1212\/WNL.0b013e3181c34b47","volume":"73","author":"S Hoops","year":"2009","unstructured":"Hoops S, Nazem S, Siderowf AD et al (2009) Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 73:1738\u20131745. https:\/\/doi.org\/10.1212\/WNL.0b013e3181c34b47","journal-title":"Neurology"},{"key":"2983_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1159\/000341998","volume":"11","author":"AA Kehagia","year":"2013","unstructured":"Kehagia AA, Barker RA, Robbins TW (2013) Cognitive impairment in parkinson\u2019s disease: the dual syndrome hypothesis. Neurodegener Dis 11:79\u201392. https:\/\/doi.org\/10.1159\/000341998","journal-title":"Neurodegener Dis"},{"key":"2983_CR28","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1002\/mds.23823","volume":"26","author":"I Litvan","year":"2011","unstructured":"Litvan I, Aarsland D, Adler C et al (2011) MDS task force on mild cognitive impairment in parkinson\u2019s disease: critical review of PD-MCI. Mov Disord 26:1814\u20131824. https:\/\/doi.org\/10.1002\/mds.23823","journal-title":"Mov Disord"},{"key":"2983_CR29","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/mds.24893","volume":"27","author":"I Litvan","year":"2012","unstructured":"Litvan I, Goldman JG, Tr\u00f6ster AI et al (2012) Diagnostic criteria for mild cognitive impairment in parkinson\u2019s disease: movement disorder society task force guidelines. Mov Disord 27:349\u2013356. https:\/\/doi.org\/10.1002\/mds.24893","journal-title":"Mov Disord"},{"key":"2983_CR30","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s11055-008-9077-3","volume":"38","author":"IV Litvinenko","year":"2008","unstructured":"Litvinenko IV, Odinak MM, Mogil\u2019naya VI, Emelin AY (2008) Efficacy and safety of galantamine (reminyl) for dementia in patients with parkinson\u2019s disease (an open controlled trial). Neurosci Behav Physiol 38:937\u2013945. https:\/\/doi.org\/10.1007\/s11055-008-9077-3","journal-title":"Neurosci Behav Physiol"},{"key":"2983_CR31","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/ane.12259","volume":"130","author":"R Lorenz","year":"2014","unstructured":"Lorenz R, Samnick S, Dillmann U et al (2014) Nicotinic \u03b14\u03b22 acetylcholine receptors and cognitive function in Parkinson\u2019s disease. Acta Neurol Scand 130:164\u2013171. https:\/\/doi.org\/10.1111\/ane.12259","journal-title":"Acta Neurol Scand"},{"key":"2983_CR32","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41531-024-000823-x","volume":"10","author":"E Mantovani","year":"2024","unstructured":"Mantovani E, Martini A, Dinoto A et al (2024) Biomarkers for cognitive impairment in alpha synucleinopathies: an overview of systemative reviews and meta-analyses. NPJ Park Dis 10:211. https:\/\/doi.org\/10.1038\/s41531-024-000823-x","journal-title":"NPJ Park Dis"},{"key":"2983_CR33","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3389\/fnins.2016.00451","volume":"10","author":"S Maramai","year":"2016","unstructured":"Maramai S, Gemma S, Brogi S et al (2016) Dopamine D3 receptor antagonists as potential therapeutics for the treatment of neurological diseases. Front Neurosci 10:451. https:\/\/doi.org\/10.3389\/fnins.2016.00451","journal-title":"Front Neurosci"},{"key":"2983_CR34","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/mds.27898","volume":"35","author":"E Martinez","year":"2020","unstructured":"Martinez E, Pasquereau B, Saga Y, Metereau E, Tremblay L (2020) The anterior caudate nucleus supports impulsive choice triggered by pramipexole. Mov Disord 35:296\u2013305. https:\/\/doi.org\/10.1002\/mds.27898","journal-title":"Mov Disord"},{"key":"2983_CR35","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1136\/jnnp.2006.098079","volume":"77","author":"SA Molloy","year":"2006","unstructured":"Molloy SA, Rowan EN, O\u2019Brien JT, McKeith IG, Wesnes K, Burn DJ (2006) Effect of Levodopa on cognitive function in parkinson\u2019s disease with and without dementia and dementia with lewy bodies. J Neurol Neurosurg Psychiatr 77:1323\u20131328. https:\/\/doi.org\/10.1136\/jnnp.2006.098079","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"2983_CR36","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1093\/brain\/awt247","volume":"136","author":"ML M\u00fcller","year":"2013","unstructured":"M\u00fcller ML, Albin RL, Kotagal V et al (2013) Thalamic cholinergic innervation and postural sensory integration function in parkinson\u2019s disease. Brain 136:3282\u20133289. https:\/\/doi.org\/10.1093\/brain\/awt247","journal-title":"Brain"},{"key":"2983_CR37","unstructured":"Patel PH, Gupta V (2023) Rivastigmine. StatPearls Publishing. Retrieved April 3 2025, from http:"},{"key":"2983_CR38","doi-asserted-by":"publisher","first-page":"580586","DOI":"10.1001\/jamaneurol.2013.2110","volume":"70","author":"KF Pedersen","year":"2013","unstructured":"Pedersen KF, Larsen JP, Tysnes OB, Alves G (2013) Prognosis of mild cognitive impairment in early Parkinson disease: the Norweigian ParkWest study. JAMA Neurol 70:580586. https:\/\/doi.org\/10.1001\/jamaneurol.2013.2110","journal-title":"JAMA Neurol"},{"key":"2983_CR39","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1212\/WNL.0000000000003634","volume":"88","author":"KF Pedersen","year":"2017","unstructured":"Pedersen KF, Larsen JP, Tysnes OB, Alves G (2017) Natural course of mild cognitive impairment in Parkinson disease. Neurology 88:767\u2013774. https:\/\/doi.org\/10.1212\/WNL.0000000000003634","journal-title":"Neurology"},{"key":"2983_CR40","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/mds.22560","volume":"24","author":"JB Pereira","year":"2009","unstructured":"Pereira JB, Junqu\u00e9 C, Marti MJ, Ramirez-Ruiz B, Bargallo N, Tolosa E (2009) Neuroanatomical substrate of visuospatial and visuoperceptual impairment in parkinson\u2019s disease. Mov Disord 24:1193\u20131199. https:\/\/doi.org\/10.1002\/mds.22560","journal-title":"Mov Disord"},{"key":"2983_CR41","doi-asserted-by":"publisher","first-page":"16001","DOI":"10.1038\/npjparkd.2016.1","volume":"2","author":"S Perez-Lloret","year":"2016","unstructured":"Perez-Lloret S, Barrantes FJ (2016) Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson\u2019s disease. NPJ Park Dis 2:16001","journal-title":"NPJ Park Dis"},{"key":"2983_CR42","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1111\/j.1742-1241.2008.01869.x","volume":"62","author":"W Poewe","year":"2008","unstructured":"Poewe W, Gauthier S, Aarsland D et al (2008) Diagnosis and management of parkinson\u2019s disease dementia. Int J Clin Pract 62:1581\u20131587. https:\/\/doi.org\/10.1111\/j.1742-1241.2008.01869.x","journal-title":"Int J Clin Pract"},{"key":"2983_CR43","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.cpet.2009.12.004","volume":"5","author":"KL Poston","year":"2010","unstructured":"Poston KL, Eidelberg D (2010) FDG PET in the evaluation of parkinson\u2019s disease. PET Clin 5:55\u201364. https:\/\/doi.org\/10.1016\/j.cpet.2009.12.004","journal-title":"PET Clin"},{"key":"2983_CR44","doi-asserted-by":"publisher","first-page":"e9275","DOI":"10.1590\/1414-431x20209275","volume":"53","author":"B Qin","year":"2020","unstructured":"Qin B, Yang MX, Gao W et al (2020) Voxel-wise meta-analysis of structural changes in Gray matter of parkinson\u2019s disease patients with mild cognitive impairment. Braz J Med Biol Res 53:e9275. https:\/\/doi.org\/10.1590\/1414-431x20209275","journal-title":"Braz J Med Biol Res"},{"key":"2983_CR45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.37349\/ent.2023.00036","volume":"3","author":"K Radad","year":"2023","unstructured":"Radad K, Moldizo R, Krewenka C, Kranner B, Rausch WD (2023) Pathophysiology of non-motor signs in parkinson\u2019s disease: some recent updating with brief presentation. Explor Neuroprotective Ther 3:24\u201346. https:\/\/doi.org\/10.37349\/ent.2023.00036","journal-title":"Explor Neuroprotective Ther"},{"key":"2983_CR46","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00702-020-02259-y","volume":"128","author":"D Rinaldi","year":"2021","unstructured":"Rinaldi D, Sforza M, Assogna F et al (2021) Safinamide improves executive functions in fluctuating parkinson\u2019s disease patients: an exploratory study. J Neural Trans (Vienna) 128:273\u2013277. https:\/\/doi.org\/10.1007\/s00702-020-02259-y","journal-title":"J Neural Trans (Vienna)"},{"key":"2983_CR47","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3233\/JPD-181306","volume":"8","author":"M Roheger","year":"2018","unstructured":"Roheger M, Kalbe E, Liepelt-Scarfone I (2018) Progression of cognitive decline in parkinson\u2019s disease. J Parkinsons Dis 8:183\u2013193. https:\/\/doi.org\/10.3233\/JPD-181306","journal-title":"J Parkinsons Dis"},{"key":"2983_CR48","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1017\/cjn.2018.21","volume":"45","author":"MA Roy","year":"2018","unstructured":"Roy MA, Doiron M, Talon-Croteau J, Dupre N, Simard M (2018) Effects of antiparkinson medication on cognition in parkinson\u2019s disease: a systematic review. Can J Neurol Sci 45:375\u2013404. https:\/\/doi.org\/10.1017\/cjn.2018.21","journal-title":"Can J Neurol Sci"},{"key":"2983_CR49","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.parkreldis.2019.04.020","volume":"65","author":"D Saredakis","year":"2019","unstructured":"Saredakis D, Collins-Praino LE, Gutteridge DS, Stephan BC, Keage HA (2019) Conversion to MCI and dementia in parkinson\u2019s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord 65:20\u201331. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.04.020","journal-title":"Parkinsonism Relat Disord"},{"key":"2983_CR50","doi-asserted-by":"publisher","first-page":"108880","DOI":"10.1016\/j.neuropharm.2021.108880","volume":"203","author":"JS Schneider","year":"2022","unstructured":"Schneider JS, Kortagere S (2022) Currrent concepts in treating mild cognitive impairment in parkinson\u2019s disease. Neuropharmacology 203:108880. https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108880","journal-title":"Neuropharmacology"},{"key":"2983_CR51","doi-asserted-by":"publisher","first-page":"120077","DOI":"10.1016\/j.jns.2021.120077","volume":"432","author":"E Severiano","year":"2022","unstructured":"Severiano E, Sousa C, Alarac\u00e3o J, Martins IP, Ferreira JJ (2022) Frequency of dementia in parkinson\u2019s disease: a systematic review and meta-analysis. J Neurol Sci 432:120077. https:\/\/doi.org\/10.1016\/j.jns.2021.120077","journal-title":"J Neurol Sci"},{"key":"2983_CR52","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1176\/aapi.ajp.2015.14121582","volume":"172","author":"C Stinton","year":"2015","unstructured":"Stinton C, McKeith I, Taylor JP et al (2015) Pharmacological management of lewy body dementia: a systematic review and meta-analysis. Am J Psychiatry 172:731\u2013742. https:\/\/doi.org\/10.1176\/aapi.ajp.2015.14121582","journal-title":"Am J Psychiatry"},{"key":"2983_CR53","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3390\/bs11040054","volume":"11","author":"C Sun","year":"2021","unstructured":"Sun C, Armstrong MJ (2021) Treatment of parkinson\u2019s disease with cognitive impairment: current approaches and future directions. Behav Sci (Basel) 11:54. https:\/\/doi.org\/10.3390\/bs11040054","journal-title":"Behav Sci (Basel)"},{"key":"2983_CR54","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0079-6123(10)84008-7","volume":"184","author":"CC Tang","year":"2010","unstructured":"Tang CC, Eidelberg D (2010) Abnormal metabolic brain networks in parkinson\u2019s disease from blackboard to bedside. Prog Brain Res 184:161\u2013176. https:\/\/doi.org\/10.1016\/S0079-6123(10)84008-7","journal-title":"Prog Brain Res"},{"key":"2983_CR55","doi-asserted-by":"publisher","first-page":"e0152716","DOI":"10.1371\/journal.pone.0152716","volume":"11","author":"Y Tang","year":"2016","unstructured":"Tang Y, Ge J, Liu F et al (2016) Cerebral metabolic differences associated with cognitive impairment in parkinson\u2019s disease. PLoS ONE 11:e0152716. https:\/\/doi.org\/10.1371\/journal.pone.0152716","journal-title":"PLoS ONE"},{"key":"2983_CR56","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/s0140-6736(85)91631-9","volume":"1","author":"A Taylor","year":"1985","unstructured":"Taylor A, Saint-Cyr JA, Lang AE (1985) Dementia prevalence in parkinson\u2019s disease. Lancet 1:1037. https:\/\/doi.org\/10.1016\/s0140-6736(85)91631-9","journal-title":"Lancet"},{"key":"2983_CR57","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/mds.28360","volume":"36","author":"S van der Zee","year":"2021","unstructured":"van der Zee S, M\u00fcller ML, Kanel P, van Laar T, Bohnen NI (2021) Cholinergic denervation patterns across cognitive domains in parkinons\u2019s disease. Mov Disord 36:642\u2013650. https:\/\/doi.org\/10.1002\/mds.28360","journal-title":"Mov Disord"},{"key":"2983_CR58","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3233\/JPD-230129","volume":"14","author":"MA Weber","year":"2024","unstructured":"Weber MA, Kerr G, Thangavel R et al (2024) Alpha-synuclein pre-formed fibrils injected into prefrontal cortex primarily spread to cortical and subcortical structures. J Parkinsons Dis 14:81\u201394. https:\/\/doi.org\/10.3233\/JPD-230129","journal-title":"J Parkinsons Dis"},{"key":"2983_CR59","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1136\/jnnp-2013-305277","volume":"84","author":"CH Williams-Gray","year":"2013","unstructured":"Williams-Gray CH, Mason SL, Evans JR et al (2013) The campaign study of parkinson\u2019s disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatr 84:1258\u20131264. https:\/\/doi.org\/10.1136\/jnnp-2013-305277","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"2983_CR60","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1001\/jamaneurol.2017.3713","volume":"75","author":"JR Winer","year":"2018","unstructured":"Winer JR, Maass A, Pressman P et al (2018) Associations between tau, \u03b2-amyloid, and cognition in Parkinson disease. JAMA Neurol 75:227\u2013235. https:\/\/doi.org\/10.1001\/jamaneurol.2017.3713","journal-title":"JAMA Neurol"},{"key":"2983_CR61","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.parkreldis.2022.06.004","volume":"101","author":"YY Wong","year":"2022","unstructured":"Wong YY, Wu CY, Yu D et al (2022) Biofluid markers of blood-brain barrier disruption and neurodegeneration in lewy body spectrum diseases: a systematic review and meta-analysis. Parkinsonism Relat Disord 101:119\u2013128. https:\/\/doi.org\/10.1016\/j.parkreldis.2022.06.004","journal-title":"Parkinsonism Relat Disord"},{"key":"2983_CR62","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1007\/s00415-016-8122-3","volume":"263","author":"Y Xu","year":"2016","unstructured":"Xu Y, Yang J, Hu X, Shang H (2016) Voxel-based meta-analysis of Gray matter volume reductions associated with cognitive impairment in parkinson\u2019s disease. J Neurol 263:1178\u20131187. https:\/\/doi.org\/10.1007\/s00415-016-8122-3","journal-title":"J Neurol"},{"key":"2983_CR63","unstructured":"Zafar S, Yaddanapudi SS (2023) Parkinson disease. StatPearls Publishing.\u00a0Retrieved January 7, 2025, from\u00a0http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470193\/"},{"key":"2983_CR64","doi-asserted-by":"publisher","first-page":"111973","DOI":"10.1016\/j.bbr.2019.111973","volume":"371","author":"D Zheng","year":"2019","unstructured":"Zheng D, Chen C, Song W et al (2019) Regional Gray matter reductions associated with mild cognitive impairment in parkinson\u2019s disease: a meta-analysis of voxel-based morphometry studies. Behav Brain Res 371:111973. https:\/\/doi.org\/10.1016\/j.bbr.2019.111973","journal-title":"Behav Brain Res"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-02983-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-025-02983-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-02983-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T14:15:44Z","timestamp":1757254544000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-025-02983-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":64,"alternative-id":["2983"],"URL":"https:\/\/doi.org\/10.1007\/s00702-025-02983-3","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Anonymized data not published within this article will be made available by request from any qualified investigator.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}}]}}